이 누리집은 대한민국 공식 전자정부 누리집입니다.

한상넷

비즈니스 정보

Biz News Korea(Eng)

Boryung Pharm signs in-licensing deal on ovarian cancer drug with Spanish firm

Collected: 2017.11.08

Distributed: 2017.11.09

Source: Go Direct

South Korea’s Boryung Pharmaceutical Co. Wednesday announced it has signed an exclusive agreement with Spain-based pharmaceutical company PharmaMar SA to develop and market the latter’s Zepsyre, an investigational drug to treat ovarian cancer, in the Korean market.

At 2:00 p.m. Wednesday, shares of Boryung Pharm were up 1.7 percent at 43,050 won ($38).

Zepsyre is currently in phase III trials of ovarian cancer patients resistant to platinum-based chemotherapy and small cell lung cancer patients whose prognosis is poor.

Previous studies showed the drug is more effective than existing therapies and has fewer side effects such as hair loss and inflammation, according to Boryung Pharm.

Headquartered in Madrid, PharmaMar is a biopharmaceutical company dedicated to develop marine-derived oncology drugs.

By Kim Hye-soon and Minu Kim

List

Previous: S. Korea to enhance anti-seismic strength of two new nuclear reactors under construction

Next: KEPCO becomes world’s largest operator of ESS for frequency regulation